THE FIRST CLINICAL EXPERIENCE WITH AFATINIB IN RUSSIAN FEDERATION
https://doi.org/10.21518/2079-701X-2016-10-66-72
Abstract
Randomized clinical trials results have shown the advantage of non-selective EGFR tyrosine kinase inhibitor 2nd generation – afatinib compared with platinum-based chemotherapy in adenocarcinoma EGFR-positive patients in both the first and second-line of treatment. Shown significant improvement in PFS compared with standard platinum contain regimen and gefitinib in the first line of treatment. Also afatinib demonstrated the efficacy in the second line of treatment of squamous cell carcinoma of lung. The advantage of OS demonstrated in the subgroup of patients with Del19 in the global randomized clinical trials. According to the local experience FSBSI «Russian Cancer Research Center n.a. N.N.Blokhin» ORR afatinib therapy was 62.7% in the tumor growth control 94.1%. Median PFS – 18.0 months. The most common adverse events observed a rash, paronychia, and diarrhea requiring dose reduction of up to 30 and 20 mg / day, 34.5% and 16.4% of patients, espectively. On the whole, marked by a favorable toxicity profile and improve the quality of patients life.
About the Authors
К. К. LAKTIONOV
FSBSI «Russian Cancer Research Center n.a. N.N. Blokhin»
Russian Federation
MD
Russian Federation
MD
М. V. PEREGUDOVA
FSBSI «Russian Cancer Research Center n.a. N.N. Blokhin»
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
V. V. BREDER
FSBSI «Russian Cancer Research Center n.a. N.N. Blokhin»
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
E. V. REUTOVA
FSBSI «Russian Cancer Research Center n.a. N.N. Blokhin»
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
D. A. PEREGUDOV
FSBSI «Russian Cancer Research Center n.a. N.N. Blokhin»
Russian Federation
Russian Federation
M. S. ARDZINBA
FSBSI «Russian Cancer Research Center n.a. N.N. Blokhin»
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
P. A. CHERNENKO
FSBSI «Russian Cancer Research Center n.a. N.N. Blokhin»
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
D. T. MARINOV
FSBSI «Russian Cancer Research Center n.a. N.N. Blokhin»
Russian Federation
Russian Federation
References
1. Imyanitov EN, Demidova IA, Gordiev MG et al. Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer. Molecular Diagnosis & Therapy, 2016 Aug, 20(4): 401-6.
2. Reguart N, Remon J. Common EGFR-mutated subgroups (Del19/L858R) in advanced nonsmall- cell lung cancer: chasing better outcomes with tyrosine-kinase inhibitors. 10.2217/ FON.15.15 © 2015 Future Medicine Ltd.
3. Mok T, Wu Y-L, Throngprasert S et al. Gefitinib or Carboplatin-Paclitaxel in pulmonary adenocarcinoma. The New England Journal of Medicine, 2009, 361: 947-957.
4. Han JY, Park K, Kim SW et al. First-signal: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung; Journal of Clinical Oncology, 2012, 30:1122-8. doi: 10.1200/JCO.2011.36.8456.
5. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factorreceptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncology, 2010, 11: 121-128.
6. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for Non-Small-Cell lung cancer with mutated EGFR. The New England Journal of Medicine, 2010, 362: 2380- 2388.
7. Zhou C, Wu Y-L, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive nonsmall- cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncology, 2011, 12: 735-742.
8. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standart chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology, 2012, 13: 239-246.
9. Chih-Hsin Yang J et al. Afatinib versus cisplatin- based chemotherapy for EGFR mutationpositive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncology, 2015, 16(2): 141-151. DOI: 10.1016/S1470-2045(14)71173-8.
10. Solca F, Dahl G, Zoephel A, Bader G , Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR. Target binding properties and cellular activity of afatinib (BBW 2992), in irreversible ErbB family blocker. J Pharmacol Exp Ther, 2012,343: 342-350.
11. Li D, Ambrogio L, Shimamura T et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene, 2008, 27: 4702-11.
12. Modjtahedi H et al. A comprehensive review of the preclinical efficacy profile of the ErbB familyblocker afatinib in cancer. Naunyn-Schmiedeberg’sArch Pharmacol, 2014, 387:505-521.
13. Горбунова В.А. Афатиниб – первый селективный необратимый ингибитор семейства ErbB. Эффективная Фармакотерапия. Онкология, гематология и радиология, 2014, 2(37): 20-28./ Gorbunova V.A. Afatinib is the first selective non-eversible nhibitor of ErbB family. Effektivnaya Farmakoterapia. Onkologia, Gematologia I Radiologia, 2014, 2(37): 20-28.
14. Sequist L, Chih-Hsin Yang J, Yamamoto N et al. Phase III study of afatinib or cisplatin pluspemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol., 2013, 31: 3327-3334.
15. Wu YL, Zhou C, Hu CP et al. Afatinib versus cisplatin plus gemcitabine for fi rst-line treatment of Asian patients with advanced nonsmall- cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol, 2014, 15: 213-22.
16. Keunchil Park, Eng-Huat Tan et al. Afatinib versus gefi tinib as fi rst-line treatment of patients with EGFR mutation-positive nonsmall-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomized controlled trial. Lancet Oncol, 2016, 17: 577-89.
17. Hall PE, Spicer J, Popat S. Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. Future Oncol, 2015, 11(15): 2175-2191.
18. Schuler M, Yang JC-H et al. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/ gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Annals of Oncology 00: 1-7, 2016. doi:10.1093/annonc/mdv597.
19. Онкология. Клинические рекомендации под редакцией академика РАН Давыдова М.И. Москва 2015./Oncology Clinical Recommendations ed. By Academician of RAS Davydov M.I.
20. «Федеральные клинические рекомендации по диагностике и лечению больных раком легкого». Ассоциация онкологов России. Москва 2014г. http://www.oncology.ru/association/ clinical-guidelines/2014/small-cell-lungcancer/. Federal Clinical Recommendations on Diagnostics and Therapy of Pulmonary Cancer. Russian Oncologist Association. Moscow 2014. http://www.oncology.ru/association/clinicalguidelines/ 2014/small-cell-lung-cancer/
21. NCCN Clinical Practice Guidelines in Oncology “Non-Small Cell Lung Cancer. Version 4.2016. http://www.nccn.org/professionals/physician_ gls/pdf/nscl.pdf.
22. Reck M, Popat S et al. ESMO Clinical Practice Guidelines: Metastatic Non-Small-Cell Lung Cancer. Ann Oncol, 2014, 25(suppl 3): iii27-iii39. http://www.esmo.org/Guidelines/Lung- ancer/ Metastatic-Non-Small-Cell-Lung-Cancer.
23. Masters GA, Temin S et al. Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Published online ahead of print at www.jco.org on August 31, 2015. doi:10.1200/JCO.2014.60.6624 Clin Oncol, 33. © 2015 by American Society of Clinical Oncology.
Review
For citations:
LAKTIONOV КК, PEREGUDOVA МV, BREDER VV, REUTOVA EV, PEREGUDOV DA, ARDZINBA MS, CHERNENKO PA, MARINOV DT. THE FIRST CLINICAL EXPERIENCE WITH AFATINIB IN RUSSIAN FEDERATION. Meditsinskiy sovet = Medical Council. 2016;(10):66-72. (In Russ.) https://doi.org/10.21518/2079-701X-2016-10-66-72
Views:
742
Email this article 